Company intelligence / Profile preview

Pennant Biogroup

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Pennant Biogroup is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative RNA-based therapeutics. The company utilizes its proprietary P-GALA delivery platform to design highly stable and potent small interfering RNA (siRNA) and antisense oligonucleotide (ASO) drugs. Pennant Biogroup's primary focus is on treating chronic diseases with high unmet medical needs, including chronic hepatitis B, dyslipidemia, and other metabolic disorders. By optimizing delivery to the liver via GalNAc-mediated uptake, the company aims to provide long-acting, transformative treatments for global patient populations.

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Small interfering RNARNA therapy
Industry: Biotech

Beyond the preview

Go deeper on Pennant Biogroup.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pennant Biogroup.

Explore the full profile